Kenneth Millar

Title: Innovations of Kenneth Millar in Antibody Technology

Introduction

Kenneth Millar is a notable inventor based in Twyford, GB. He has made significant contributions to the field of biotechnology, particularly in the development of crosslinked antibodies. His innovative work has implications for both diagnosis and therapy in medical applications.

Latest Patents

Kenneth Millar holds a patent for "Crosslinked antibodies and processes for their preparation." This patent describes cross-linked antibody conjugates that feature at least one interchain bridge containing a reporter or effector molecule. The bridge is strategically located away from the antigen binding domains of the antibody, enhancing the binding capacity of the conjugates. In vivo studies indicate that these conjugates exhibit good blood clearance and favorable tumor-to-blood and tumor-to-bone ratios, making them useful in the diagnosis and treatment of tumors. The preparation of these conjugates involves the reaction of a cross-linking reagent with an antibody.

Career Highlights

Millar is associated with Celltech Therapeutics Limited, a company known for its advancements in biopharmaceuticals. His work at Celltech has allowed him to focus on innovative solutions that address critical health challenges.

Collaborations

Throughout his career, Kenneth Millar has collaborated with esteemed colleagues such as Stephen Keith Rhind and Thomas A Millican. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking technologies.

Conclusion

Kenneth Millar's contributions to the field of antibody technology exemplify the impact of innovation in biotechnology. His patent on crosslinked antibodies represents a significant advancement in medical diagnostics and therapeutics.